JP2013529181A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013529181A5 JP2013529181A5 JP2013501487A JP2013501487A JP2013529181A5 JP 2013529181 A5 JP2013529181 A5 JP 2013529181A5 JP 2013501487 A JP2013501487 A JP 2013501487A JP 2013501487 A JP2013501487 A JP 2013501487A JP 2013529181 A5 JP2013529181 A5 JP 2013529181A5
- Authority
- JP
- Japan
- Prior art keywords
- pkd1
- antibody
- human mammal
- mammal
- endogenous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101001026870 Homo sapiens Serine/threonine-protein kinase D1 Proteins 0.000 claims 14
- 102100037310 Serine/threonine-protein kinase D1 Human genes 0.000 claims 14
- 101100029888 Homo sapiens PKD1 gene Proteins 0.000 claims 6
- 101150056230 PKD1 gene Proteins 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 241000124008 Mammalia Species 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 230000002452 interceptive effect Effects 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 230000007812 deficiency Effects 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 210000002569 neuron Anatomy 0.000 claims 3
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 230000007547 defect Effects 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 239000004055 small Interfering RNA Substances 0.000 claims 2
- 230000009261 transgenic effect Effects 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 241000283984 Rodentia Species 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000004498 neuroglial cell Anatomy 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 150000003384 small molecules Chemical group 0.000 claims 1
- 230000006886 spatial memory Effects 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31759810P | 2010-03-25 | 2010-03-25 | |
| US61/317,598 | 2010-03-25 | ||
| PCT/US2011/029806 WO2011119842A1 (en) | 2010-03-25 | 2011-03-24 | Compositions and methods for treating neurological disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013529181A JP2013529181A (ja) | 2013-07-18 |
| JP2013529181A5 true JP2013529181A5 (cg-RX-API-DMAC7.html) | 2014-05-08 |
Family
ID=44673620
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013501487A Pending JP2013529181A (ja) | 2010-03-25 | 2011-03-24 | 神経障害を治療するための組成物および方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US9359445B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2550361B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2013529181A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011119842A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3030902B1 (en) * | 2013-08-07 | 2019-09-25 | Friedrich Miescher Institute for Biomedical Research | New screening method for the treatment friedreich's ataxia |
| GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
| KR102620328B1 (ko) | 2014-10-03 | 2024-01-02 | 콜드스프링하버러보러토리 | 핵 유전자 산출량의 표적화 증강 |
| KR20220105174A (ko) | 2015-10-09 | 2022-07-26 | 유니버시티 오브 사우스앰톤 | 유전자 발현의 조절 및 탈조절된 단백질 발현의 스크리닝 |
| US11096956B2 (en) | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
| CN109312343B (zh) | 2015-12-14 | 2022-09-27 | 冷泉港实验室 | 用于治疗常染色体显性精神发育迟滞5型和Dravet综合征的反义寡聚体 |
| JP7324709B2 (ja) * | 2017-02-09 | 2023-08-10 | コグノア，インク． | デジタル個別化医療のためのプラットフォームとシステム |
| EP3611696A4 (en) * | 2017-02-16 | 2021-02-17 | Kyoto University | CELL EVALUATION PROCESS, CELL EVALUATION DEVICE AND CELL EVALUATION PROGRAM |
| AU2018308088B2 (en) | 2017-07-25 | 2025-05-29 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| SMT202400071T1 (it) | 2017-08-25 | 2024-03-13 | Stoke Therapeutics Inc | Oligomeri antisenso per il trattamento di condizioni e malattie |
| US12060558B2 (en) | 2018-05-04 | 2024-08-13 | Stoke Therapeutics, Inc. | Methods and compositions for treatment of cholesteryl ester storage disease |
| CA3127113A1 (en) | 2019-01-30 | 2020-08-06 | Dongxu Sun | Anti-gal3 antibodies and uses thereof |
| CA3173647A1 (en) | 2020-05-11 | 2021-11-18 | Isabel AZNAREZ | Opa1 antisense oligomers for treatment of conditions and diseases |
| AU2021278935A1 (en) | 2020-05-26 | 2022-12-08 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking Galectin-3 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992007065A1 (en) | 1990-10-12 | 1992-04-30 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Modified ribozymes |
| DE4216134A1 (de) | 1991-06-20 | 1992-12-24 | Europ Lab Molekularbiolog | Synthetische katalytische oligonukleotidstrukturen |
| US5652094A (en) | 1992-01-31 | 1997-07-29 | University Of Montreal | Nucleozymes |
| EP0681482B1 (en) | 1993-01-22 | 2005-12-07 | University Research Corporation | Localization of therapeutic agents |
| US5627053A (en) | 1994-03-29 | 1997-05-06 | Ribozyme Pharmaceuticals, Inc. | 2'deoxy-2'-alkylnucleotide containing nucleic acid |
| US5716824A (en) | 1995-04-20 | 1998-02-10 | Ribozyme Pharmaceuticals, Inc. | 2'-O-alkylthioalkyl and 2-C-alkylthioalkyl-containing enzymatic nucleic acids (ribozymes) |
| US7964598B2 (en) | 1995-10-17 | 2011-06-21 | The J. David Gladstone Institutes | ApoE4 domain interaction inhibitors and methods of use thereof |
| CA2253382A1 (en) | 1996-01-16 | 1997-07-24 | Ribozyme Pharmaceuticals, Inc. | Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules |
| US5849902A (en) | 1996-09-26 | 1998-12-15 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
| DE19650758C1 (de) * | 1996-12-06 | 1998-01-02 | Deutsches Krebsforsch | PKD1-Fragmente mit Bindungsregionen für PKD1-spezifische Antikörper |
| US6124272A (en) * | 1999-04-09 | 2000-09-26 | Isis Pharmaceutical Inc. | Antisense modulation of PDK-1 expression |
| US7491805B2 (en) | 2001-05-18 | 2009-02-17 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| US20050233329A1 (en) | 2002-02-20 | 2005-10-20 | Sirna Therapeutics, Inc. | Inhibition of gene expression using duplex forming oligonucleotides |
| AU2004266311B2 (en) | 2001-05-18 | 2009-07-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| US20050282188A1 (en) | 2001-05-18 | 2005-12-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
| GB0117326D0 (en) | 2001-07-16 | 2001-09-05 | Univ Aberdeen | Napthoquinone-type inhibitors of protein aggregation |
| DK1427709T3 (da) | 2001-09-21 | 2006-04-03 | Mitsubishi Pharma Corp | 3-substituerede 4-pyrimidonderivater |
| US20040121407A1 (en) * | 2002-09-06 | 2004-06-24 | Elixir Pharmaceuticals, Inc. | Regulation of the growth hormone/IGF-1 axis |
| EP1692128A1 (en) | 2003-11-19 | 2006-08-23 | Signal Pharmaceuticals LLC | Indazole compounds and methods of use thereof as protein kinase inhibitors |
| CN102603581B (zh) | 2005-06-22 | 2015-06-24 | 普莱希科公司 | 作为蛋白质激酶抑制剂的吡咯并[2,3-b]吡啶衍生物 |
| GB0602178D0 (en) * | 2006-02-03 | 2006-03-15 | Merck Sharp & Dohme | Therapeutic treatment |
| MX2008013718A (es) | 2006-04-26 | 2008-11-06 | Cancer Rec Tech Ltd | Compuestos de amino-etil-amino-arilo y su uso. |
| US20090175852A1 (en) | 2006-06-06 | 2009-07-09 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
| US8240498B2 (en) | 2006-10-31 | 2012-08-14 | Crown Packaging Technology, Inc. | Resealable closure |
| US8618063B2 (en) * | 2008-04-09 | 2013-12-31 | The Board Of Trustees Of The University Of Illinois | Method for treating a synucleinopathy |
| EP2297311A1 (en) * | 2008-06-06 | 2011-03-23 | Medizinische Universität Graz | Compounds reducing or inhibiting the expression of pkd1 for diagnosis and therapy of brain tumors |
| ES2385276B1 (es) | 2010-02-25 | 2013-07-05 | Universidad Del País Vasco | Compuestos para el tratamiento de alzheimer. |
-
2011
- 2011-03-24 EP EP11760223.5A patent/EP2550361B1/en not_active Not-in-force
- 2011-03-24 WO PCT/US2011/029806 patent/WO2011119842A1/en not_active Ceased
- 2011-03-24 JP JP2013501487A patent/JP2013529181A/ja active Pending
-
2012
- 2012-09-24 US US13/625,597 patent/US9359445B2/en not_active Expired - Fee Related
-
2016
- 2016-05-05 US US15/147,814 patent/US20160354372A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013529181A5 (cg-RX-API-DMAC7.html) | ||
| Carty et al. | Characterization of HTT inclusion size, location, and timing in the zQ175 mouse model of Huntington´ s disease: an in vivo high-content imaging study | |
| Hansen et al. | A novel α-synuclein-GFP mouse model displays progressive motor impairment, olfactory dysfunction and accumulation of α-synuclein-GFP | |
| Park et al. | MTERF3 is a negative regulator of mammalian mtDNA transcription | |
| Sobajima et al. | Rab11a is required for apical protein localisation in the intestine | |
| Zaharieva et al. | Concentration and localization of coexpressed ELAV/Hu proteins control specificity of mRNA processing | |
| Tanaka et al. | BEX1/ARF1A1C is required for BFA-sensitive recycling of PIN auxin transporters and auxin-mediated development in Arabidopsis | |
| Hallengren et al. | Neuronal ubiquitin homeostasis | |
| Nagara et al. | Impaired Cytoplasmic–Nuclear Transport of Hypoxia‐Inducible Factor‐1α in Amyotrophic Lateral Sclerosis | |
| HRP20231707T1 (hr) | Životinje koje nisu ljudi, koje sadrže humanizirani gen iz diferencijacijske skupine 47 | |
| JP2011501652A5 (cg-RX-API-DMAC7.html) | ||
| Tulgren et al. | The Nesprin family member ANC-1 regulates synapse formation and axon termination by functioning in a pathway with RPM-1 and β-Catenin | |
| Razafsky et al. | LINC complexes mediate the positioning of cone photoreceptor nuclei in mouse retina | |
| Navarro et al. | The nucleus is a conserved mechanosensation and mechanoresponse organelle | |
| Pelletier et al. | An early onset progressive motor neuron disorder in Scyl1-deficient mice is associated with mislocalization of TDP-43 | |
| JP2016527891A5 (cg-RX-API-DMAC7.html) | ||
| RU2019119609A (ru) | Пептиды, способные реактивировать мутанты р53 | |
| Becker et al. | Glutaminyl cyclase-mediated toxicity of pyroglutamate-beta amyloid induces striatal neurodegeneration | |
| JP2009525046A5 (cg-RX-API-DMAC7.html) | ||
| Wang et al. | Sun1 deficiency leads to cerebellar ataxia in mice | |
| Yamamoto et al. | The nebulin SH3 domain is dispensable for normal skeletal muscle structure but is required for effective active load bearing in mouse | |
| Kong et al. | Dlic1 deficiency impairs ciliogenesis of photoreceptors by destabilizing dynein | |
| Abrakhi et al. | Nanoscale analysis reveals the maturation of neurodegeneration-associated protein aggregates: grown in mRNA granules then released by stress granule proteins | |
| Tomioka et al. | Ependymal cells of the mouse brain express urate transporter 1 (URAT1) | |
| Tomioka et al. | Immunohistochemical and in situ hybridization study of urate transporters GLUT9/URATv1, ABCG2, and URAT1 in the murine brain |